For the interpretation of IHC staining, three primary sets of guidelines are used in clinical practice, namely the ISGyP recommendations [21,24,25], the 2018 ASCO/CAP guideline recommendations for HER2 testing in breast carcinoma [26], and FDA guidance [27,28]. This evidence concerns the gene ERBB2 and breast carcinoma.